Identical Twins with KD Study: A case study of two identical twins with KD shows very different onset of the symptoms of Kennedy's Disease. One twin started showing signs at age 31 whereas the other not until he was 56. There were also several other differences in how the KD impacted their lives. To access the case study, click here.
Molecular Mechanisms and Therapeutics for KD: In an attempt to develop new therapies for people with KD, a paper by Frederick J. Arnold and Diane E. Merry provides a comprehensive overview of the many ailments that people with KD encounter. To read more, click here.
Heat Shock Protein as a possible treatment for KD: It is believed that the long CAG repeat length in the androgen receptor is a mechanism that causes the protein to fold incorrectly and thus get trapped in the cell nucleus. The ability of Hsp70 to facilitate degradation of misfolded proteins makes it an attractive therapeutic target in polyQ diseases, of which KD is one. Targeting Hsp70 facilitated protein quality control for treatment of polyglutamine diseases. To learn more, click here.
Efficacy and safety of leuprorelin acetate for subjects with spinal and bulbar muscular atrophy: pooled analyses of two randomized-controlled trials. To learn more, click here.
SBMA Patients are More Likely to be Affected by Metabolic Disorders, Heart and Liver Disease. To view the study, click here.
The European Neuro Muscular Centre lay report "Towards a European Unifying Lab for Kennedy's Disease" was published. The purpose of the lay report is to share information on the workshop with the lay community, i.e. the patients and their representatives. For more info, click here.
Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophy. To learn more, click here.